

US EPA approves Amoeba's biocide for use in closed cooling systems

Lyon (France), Décembre 20th, 2022 - 5h45 pm - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the US Environmental Protection Agency (US EPA) has approved the use of the *Willaertia magna* C2c Maky as an active substance for use cooling systems.

As a result of the EPA's favorable pre-decision (see Press Release dated August 10th, 2022) and the public consultation required for any new active substance, completed on December 3rd, 2022, the amoeba *Willaertia magna* C2c Maky and the BIOMEBA products containing it are now approved in the United States for a biocidal use in closed cooling systems for the control of microbial slime (bioslime), microbially induced corrosion and general microbial flora.

"After more than 10 years of research and development, Amoéba is the very first company in the world to validate a biological biocide in the treatment of bacterial risk in water! This is a major success that the company will tend to develop over the next few years", says Fabrice Plasson, CEO of Amoéba.

Besides, to continue the strategic alignment of the company, Amoéba has initiated the withdrawal of the biocidal active substance application in Europe, as was done in Canada (see Press Release dated October 19th, 2022).

About Amoéba :

Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba *Willaertia magna* C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion (1), as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (2) in the United States. The commercialisation of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com.

1. *marketsandmarkets.com*, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

2. *Amoéba data*

Contacts:

Amoéba

Valérie FILIATRE

Deputy General Manager

+33 4 26 69 16 00

v.filiatre@amoeba-nature.com

Calyptus

Investor & Press Relations

Nicolas HELIN / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.